14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 4.350 3 days ( -4.77 % )
Last Price $47.20 0.90 %
High/ Low $47.13 - $48.37 14.22%
Chg 7 Days 12.06 % $42.12 $47.20
Chg 30 Days -0.88 % $47.62 $47.20
Chg 12 mos 120.87 % $21.37 $47.20
Trend - 3 mos 19.73 % Width: 22.64 %
Trend - 12 mos 152.31 % Width: 40.03 %
Pred. range - 3 mos $50.88 - $62.41 7.81 % - 32.22 %
Pred. range - 12 mos $90.01 - $126.04 90.69 % - 167.02 %
Short MA avg 3 mos Buy Apr 26, 2024 - 6 days
Long MA avg 3 mos Buy Apr 26, 2024 - 6 days
Short/Long MA avg 3 mos Sell Apr 19, 2024 - 11 days
Short MA avg 12 mos Buy Apr 30, 2024 - 4 days
Long MA avg 12 mos Buy Sep 08, 2023 - 165 days
Short/Long MA avg 12 mos Buy Sep 15, 2023 - 160 days
Pivot Short Sell Apr 11, 2024 - 17 days
Bollinger Buy Mar 01, 2024 - 45 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat c... CRNX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT